Bank of America’s Direxion mRNA ETF MSGR Stock Holding History

Bank of America’s Portfolio MSGR Stock Details MSGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,000	Closed	-$339K	–	8561
2022 Q3	$339K	Hold	25,000	–	–	﹤0.01%	5659
2022 Q2	$338K	Hold	25,000	–	–	﹤0.01%	5718
2022 Q1	$444K	Hold	25,000	–	–	﹤0.01%	5921
2021 Q4	$594K	Buy	+25,000	New	+$601K	﹤0.01%	5710

Other funds holding MSGR

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America's MSGR Position: Q4 2022 in Review

Bank of America sold out of Direxion mRNA ETF (MSGR) in Q4 2022, closing a stake of 25,000 shares — an estimated $339K sold.

Bank of America first reported a position in MSGR in Q4 2021 and held it in 4 quarters. The position peaked at $594K in Q4 2021. 1 fund tracked by Wall St. Rank holds MSGR as of Q4 2022.

Bank of America reported no remaining Direxion mRNA ETF position as of Q4 2022 after selling out during the quarter.
Bank of America sold 25,000 Direxion mRNA ETF shares in Q4 2022, an estimated $339K.
Bank of America first reported a position in Direxion mRNA ETF in Q4 2021 and held it in 4 quarters.
Bank of America's Direxion mRNA ETF position peaked at $594K in Q4 2021.
1 fund tracked by Wall St. Rank held Direxion mRNA ETF as of Q4 2022.

Based on Bank of America's 13F filing for Q4 2022, filed 10 Feb 2023.